Molecular mechanisms of antiestrogen action in breast cancer
- 1 January 1994
- journal article
- review article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 31 (1) , 41-52
- https://doi.org/10.1007/bf00689675
Abstract
No abstract availableKeywords
This publication has 101 references indexed in Scilit:
- Down-regulation of transforming growth factor-α by tamoxifen in human breast cancerCancer, 1993
- Droloxifene, a new anti-oestrogen in postmenopausal advanced breast cancer: Preliminary results of a double-blind dose-finding phase II trialEuropean Journal Of Cancer, 1992
- A mutation in the ligand binding domain of the androgen receptor of human INCaP cells affects steroid binding characteristics and response to anti-androgensBiochemical and Biophysical Research Communications, 1990
- Prevention of breast cancer with tamoxifen—an update on the royal Marsden Hospital pilot programmeEuropean Journal of Cancer and Clinical Oncology, 1990
- A Randomized Clinical Trial Evaluating Tamoxifen in the Treatment of Patients with Node-Negative Breast Cancer Who Have Estrogen-Receptor–Positive TumorsNew England Journal of Medicine, 1989
- Bis(4-hydroxyphenyl)[2-(phenoxysulfonyl)phenyl]methane: isolation and structure elucidation of a novel estrogen from commercial preparations of phenol red (phenolsulfonphthalein)Journal of Medicinal Chemistry, 1988
- Toremifene, a new antiestrogenic compound, for treatment of advanced breast cancer. Phase II studyEuropean Journal of Cancer and Clinical Oncology, 1988
- Human breast cancer in the athymic nude mouse: Cystostatic effects of long-term antiestrogen therapyEuropean Journal of Cancer and Clinical Oncology, 1987
- Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-ANature, 1986
- Oestrogen-responsive human breast cancer in long term tissue cultureNature, 1975